These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36964657)

  • 41. HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation.
    Mellins ED; Stern LJ
    Curr Opin Immunol; 2014 Feb; 26():115-22. PubMed ID: 24463216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural aspects of chaperone-mediated peptide loading in the MHC-I antigen presentation pathway.
    Natarajan K; Jiang J; Margulies DH
    Crit Rev Biochem Mol Biol; 2019 Apr; 54(2):164-173. PubMed ID: 31084439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of peptide repertoire selection by HLA-DM.
    Pos W; Sethi DK; Wucherpfennig KW
    Trends Immunol; 2013 Oct; 34(10):495-501. PubMed ID: 23835076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Studying MHC Class II Peptide Loading and Editing In Vitro.
    Kim A; Ishizuka IE; Hartman IZ; Poluektov Y; Narayan K; Sadegh-Nasseri S
    Methods Mol Biol; 2019; 1988():343-355. PubMed ID: 31147951
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of azapeptides as major histocompatibility complex class II protein ligands for T-cell activation.
    Hart M; Beeson C
    J Med Chem; 2001 Oct; 44(22):3700-9. PubMed ID: 11606135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structures of an MHC class II molecule with covalently bound single peptides.
    Fremont DH; Hendrickson WA; Marrack P; Kappler J
    Science; 1996 May; 272(5264):1001-4. PubMed ID: 8638119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01: BREAKING CONFINEMENT.
    Remesh SG; Andreatta M; Ying G; Kaever T; Nielsen M; McMurtrey C; Hildebrand W; Peters B; Zajonc DM
    J Biol Chem; 2017 Mar; 292(13):5262-5270. PubMed ID: 28179428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role of Molecular Flexibility in Antigen Presentation and T Cell Receptor-Mediated Signaling.
    Natarajan K; Jiang J; May NA; Mage MG; Boyd LF; McShan AC; Sgourakis NG; Bax A; Margulies DH
    Front Immunol; 2018; 9():1657. PubMed ID: 30065727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition.
    Hawse WF; Gloor BE; Ayres CM; Kho K; Nuter E; Baker BM
    J Biol Chem; 2013 Aug; 288(34):24372-81. PubMed ID: 23836912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation.
    Wieczorek M; Abualrous ET; Sticht J; Álvaro-Benito M; Stolzenberg S; Noé F; Freund C
    Front Immunol; 2017; 8():292. PubMed ID: 28367149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
    Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
    J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HLA-DM catalytically enhances peptide dissociation by sensing peptide-MHC class II interactions throughout the peptide-binding cleft.
    Reyes-Vargas E; Barker AP; Zhou Z; He X; Jensen PE
    J Biol Chem; 2020 Mar; 295(10):2959-2973. PubMed ID: 31969393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells.
    Parker R; Partridge T; Wormald C; Kawahara R; Stalls V; Aggelakopoulou M; Parker J; Powell Doherty R; Ariosa Morejon Y; Lee E; Saunders K; Haynes BF; Acharya P; Thaysen-Andersen M; Borrow P; Ternette N
    Cell Rep; 2021 May; 35(8):109179. PubMed ID: 34004174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mooring Stone-Like Arg
    Yue C; Xiang W; Huang X; Sun Y; Xiao J; Liu K; Sun Z; Qiao P; Li H; Gan J; Ba L; Chai Y; Qi J; Liu P; Qi P; Zhao Y; Li Y; Qiu HJ; Gao GF; Gao G; Liu WJ
    J Virol; 2022 Feb; 96(4):e0137821. PubMed ID: 34851145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluorogenic probes for monitoring peptide binding to class II MHC proteins in living cells.
    Venkatraman P; Nguyen TT; Sainlos M; Bilsel O; Chitta S; Imperiali B; Stern LJ
    Nat Chem Biol; 2007 Apr; 3(4):222-8. PubMed ID: 17351628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Machine learning reveals a non-canonical mode of peptide binding to MHC class II molecules.
    Andreatta M; Jurtz VI; Kaever T; Sette A; Peters B; Nielsen M
    Immunology; 2017 Oct; 152(2):255-264. PubMed ID: 28542831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.
    Crotzer VL; Glosson N; Zhou D; Nishino I; Blum JS
    Immunology; 2010 Nov; 131(3):318-30. PubMed ID: 20518820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peptide presentation by class-I major histocompatibility complex molecules.
    Nikolić-Zugić J; Carbone FR
    Immunol Res; 1991; 10(1):54-65. PubMed ID: 1865131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins.
    Zhang F; Zang TM; Stevenson EM; Lei X; Copertino DC; Mota TM; Boucau J; Garcia-Beltran WF; Jones RB; Bieniasz PD
    Proc Natl Acad Sci U S A; 2022 Oct; 119(41):e2209042119. PubMed ID: 36136978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.